Epirubicin is not Superior to Doxorubicin in the Treatment of Advanced Soft Tissue Sarcomas.The Experience of the EORTC Soft Tissue and Bone Sarcoma Group

Purpose. Doxorubicin (dox) still appears to be one of the most active drugs in the treatment of soft tissue sarcomas. However, treatment duration is limited due to cumulative cardiotoxicity. A number of small studies from single institutions have suggested activity of other analogues. In two studies...

Descripción completa

Detalles Bibliográficos
Autores principales: Nielsen, Ole S., Dombernowsky, Per, Mouridsen, Henning, Daugaard, Søren, Van Glabbeke, Martine, Kirkpatrick, Anne, Verweij, Jaap
Formato: Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2000
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2408358/
https://www.ncbi.nlm.nih.gov/pubmed/18521432
http://dx.doi.org/10.1155/S1357714X00000062

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2408358/
https://www.ncbi.nlm.nih.gov/pubmed/18521432
http://dx.doi.org/10.1155/S1357714X00000062

Ejemplares similares